74 results about "Hematological Diseases" patented technology

The invention relates to a compound according to general formula (I), which acts as a bradykinin (BK) B2 receptor antagonist; to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to said compound(s) for use as in a method of treating a skin disorder; eye disease; ear disease; mouth, throat and respiratory disease; gastrointestinal disease; liver, gallbladder and pancreatic disease; urinary tract and kidney disease; disease of male genitale organs and female genitale organs; disease of the hormone system; metabolic disease; cardiovascular disease; blood disease; lymphatic disease; disorder of the central nervous system; brain disorder; musculoskeletal system disease; allergy disorder; pain; infectious disease; inflammatory disorder; injury; immunology disorder; cancer; hereditary disease; or edema.

The invention provides a cyclic compound with a structure as shown in a formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a prodrug molecule of the cyclic compound, and a pharmaceutical composition and application of the cyclic compound or the pharmaceutically acceptable salt or the stereoisomer or the prodrug molecule of the cyclic compound. The compound can be used as a protein kinase inhibitor, has very strong inhibitory activity on FLT3 mutant kinase, has very strong proliferation inhibitory activity on Ba / F3-FLT3-ITD and stable strain cells containing drug-resistant point mutation, can inhibit proliferation, migration and invasion of various tumor cells, and especially can overcome the drug resistance of existing clinical drugs. The cyclic compound provided by the invention can be used for preparing medicines for preventing or treating FLT3 tyrosine kinase mediated diseases (such as hematological malignancies), and can be used for treating various hematological malignancies of human beings and other mammals. # imgabs0 #

The invention provides a microscopic image-based cell classification method and a blood disease identification and verification cloud platform system, and relates to the field of hematopoietic system detection, the system comprises a terminal AI processing system, a central server AI processing system and an on-demand interaction system, and the terminal AI processing system and the central server AI processing system jointly construct a two-stage intelligent identification system architecture. Through the cooperation of the above structures, the system has the following beneficial effects: 1, a two-stage AI frame is adopted, data congestion is reduced, the workload of a central server is reduced, and in addition, only necessary data is uploaded through segmented transmission of images and an on-demand interaction mechanism, so that the data transmission amount is reduced; 2, a deep learning technology is utilized to realize automatic analysis of blood cell sample and bone marrow sample images; and thirdly, a feedback mechanism is introduced, and a set of intelligent verification system for continuous learning and optimization is constructed through mutual fusion of professional experience of doctors and an advanced deep learning technology.

The invention discloses a CD7 and FAS double-gene knockout CD7 CAR-T cell and a preparation method and application thereof.By means of the method, the self-killing phenomenon of the CAR-T cell can be avoided, the cell amplification efficiency and the treatment effect can be improved, in addition, the survival ability and durability of the CAR-T cell can be remarkably enhanced, the method has remarkable advantages in treatment of T cell hematological malignancies, and the method is suitable for being used for treating T cell hematological malignancies. The method has a good application prospect and important conversion significance.

The present disclosure provides compounds of Formula (I), (II), and (III). The provided compounds are able to bind protein kinases (e.g., SIK) and may be useful in modulating (e.g., inhibiting) the activity of a protein kinase (e.g., SIK, (e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.

The application discloses a 3-(5-(aminomethyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione derivative and a synthesis method and application thereof, and relates to a 3-(5-(aminomethyl)-1-oxoisoindoline-2-yl)piperidine-2,6-dione derivative which is a compound with the following general formula (I): wherein R1 is selected from,,,,,,,,, and R2 is selected from,,, and. The compound can significantly inhibit the proliferation of leukemia, multiple myeloma, lymphoma, breast cancer, liver cancer and the like at a low dose (nanomole), can effectively degrade IKZF1, IKZF3, BRD4, GSPT1 and CK1 alpha, and has the prospect of being developed into an anti-tumor drug. The application solves the problem that the existing malignant hematological disease treatment drugs have a high safety risk.

This invention discloses the application and method of a STAT1-targeting inhibitor in the treatment of immune thrombocytopenic purpura (ITP). It employs ivermectin, a STAT1 nuclear translocation inhibitor, and fludarabine, a STAT1 activation inhibitor. By injecting either the activation inhibitor or the nuclear translocation inhibitor, the platelet count in a mouse model of ITP is increased. Fludarabine, a fluorinated nucleotide analog of vidarabine, is non-radioactive and a small-molecule phosphorylation inhibitor. Ivermectin is a small-molecule inhibitor of nuclear translocation mediated by α / β1 introgression protein. Both have high bioavailability and are widely used to treat various hematological diseases with good safety profiles. Their application in treating ITP is safe, effective, and shows high compliance.

The present invention relates to compounds having a fused, substituted tricyclic scaffold and stereo-isomeric forms, solvates, hydrates and / or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these substituted tricyclic derivatives together with pharmaceutically acceptable carrier, excipient and / or diluents. Said substituted tricyclic derivatives have been identified as especially potent ligands of FK506 binding proteins (FKBPs), especially human FKBP12, FKBP12.6, FKBP51 and FKBP52 or bacterial homologs like LpMip, CtMip, CpMip, NgMip, KpMip, BpMip, TcMip, EcFKLB, EcFKPA, PaFKLB, PaFKPA, AbFKLB, AbFKPA, and are useful for treatment of diseases such as psychiatric, metabolic, infective, neurological and haematological disorders as well as pain and cancers and as anti-inflammatory drugs. Said substituted tricyclic derivatives may further be used as agents for inducing protein-protein interactions (PPIs) acting as molecular glues.

Lentiviral vector (LV) formulations, and pharmaceutical compositions comprising such LV formulations, with improved stability and suitable for systemic administration are provided. Methods for treating disorders, especially blood disorders, using systemic administration of LV formulations are also provided.

The invention provides a blood disease AI diagnosis assisting system. The system comprises a data acquisition module used for acquiring multi-modal data; the feature extraction module is used for performing feature extraction on the multi-modal data based on a preset fusion feature extraction strategy to obtain fusion features; the scheme generation module is used for generating a reference scheme which corresponds to the fusion features and is used for blood disease auxiliary diagnosis through a preset diagnosis-assisting scheme generation strategy according to the fusion features; the score acquisition module is used for acquiring a score matrix; the evaluation module is used for determining a comprehensive score of the reference scheme as an evaluation result according to the score matrix; and the feedback adjustment module is used for adjusting hyper-parameters in a preset fusion feature extraction strategy and / or a preset diagnosis assisting scheme generation strategy according to the evaluation result. Therefore, the problem that the finally output reference pathology recognition result is inaccurate due to the fact that the data mode of pathology recognition is single in the traditional hematological disease assisted diagnosis and assisted teaching process can be solved.

CD38 is also expressed in a variety of hematological malignancies, including multiple myeloma. In the present invention, the inventors obtained a new antibody against CD38 that can be used to produce bispecific antibodies and CAR T cell populations. In particular, the inventors reported the development of Bi38-3, a new bispecific T cell engager that targets CD38 on MM cells and forms cytotoxic T cells through CD3ε. Bi38-3 lacks the Fc region of natural mAbs, which contributes to the resistance process, but triggers T cell proliferation, cytokine release, and lysis of CD38-positive MM cells in vitro. Similarly, Bi38-3 induces autologous T cells to eliminate tumor plasma cells isolated from MM patients at diagnosis and relapse. The cytotoxicity triggered by Bi38-3 is limited to cells expressing high levels of CD38 and maintains the integrity of T, B, and NK lymphocytes in vitro. Importantly, Bi38-3 rapidly reduced tumor cells in the MM1.S xenograft mouse model of human MM. In summary, the results show that the antibody of the present invention is an effective agent for specifically eliminating CD38-positive malignant cells without significantly affecting CD38-low-expressing cells, and is a promising new immunotherapy tool for treating malignant blood diseases, especially multiple myeloma.

The application provides an RT-RAP primer probe set and kit for detecting blood viruses, and belongs to the technical field of molecular biology. The primer probe set comprises a primer probe set for detecting hepatitis B virus, and / or a primer probe set for detecting hepatitis C virus, and / or a primer probe set for detecting human immunodeficiency virus. The application adopts the detection means of RT-RAA and qPCR in sequence, and can simultaneously and rapidly detect hepatitis B virus, hepatitis C virus and human immunodeficiency virus in combination with the specific primer probe set, has higher sensitivity than ordinary qPCR, greatly shortens the reaction time, and has good specificity.

The present invention relates to diarylheptanoid-based compounds and a method for inducing ex vivo expansion of hematopoietic stem cell populations. This method comprises incubating HSCs in a culture medium comprising diarylheptanoid-based compounds, leading to improved ex vivo expansion of HSCs and preservation of their major specific properties. This includes self-renewal and multilineage differentiation. These resultant enhancements demonstrate the potential of HSCs for use in treating hematological diseases and blood cancers prior to HSCT.

The invention discloses a traditional Chinese medicine composition for treating chemotherapy-related oral mucositis and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 6-12 parts of radix rehmanniae recen, 6-12 parts of radix ophiopogonis, 6-12 parts of radix scrophulariae, 6-12 parts of honeysuckle, 6-12 parts of fructus forsythiae, 3-7 parts of radix scutellariae, 1-3 parts of lotus plumule, 3-7 parts of mint and 3-7 parts of borneol. The composition has the effects of nourishing yin, clearing heat, astringing sores and promoting tissue regeneration, and clinical tests prove that the composition can remarkably reduce the occurrence rate of chemotherapy-related oral mucositis of hematological malignancy patients, relieve the damage degree of oral mucosa, shorten the lasting time of ulcer and pain and effectively improve clinical symptoms of traditional Chinese medicine, and is high in safety.

The present invention relates to a novel anti-HLA-DR IgM isotype monoclonal antibody and to the use thereof alone or in addition to anti-CD20 IgG1 or IgM isotype antibodies, in the treatment of B-phenotype lymphoid hemopathies, and in particular of non-Hodgkin lymphoma B, chronic lymphocytic leukemia (CLL) and B-cell malignant lymphoid hemopathies in general.

The invention belongs to the technical field of biological detection, and provides a visualization method for rapidly detecting bovine babesia disease and application of the method. Specific SBP2 multi-copy conservative genes of bovine babesia are targeted, high-specificity ERA primers are designed, an ERA-CRISPR / Cas12a two-stage signal amplification system is established, specific recognition is conducted on amplification products through a CRISPR / Cas12a system, and the specific Babesia disease is detected. And activating a fluorescence signal. Results show that the method has no cross reaction on five common blood pathogens such as babesia vole and the like, the detection sensitivity for the babesia bovis reaches 10 copies / mu L, and on-site visual diagnosis can be completed within 40 minutes.

The present invention relates to compounds and compositions for the treatment of hematological disorders. The present invention provides methods for the treatment of hematological disorders, such as acute myeloid leukemia, using substituted heterocyclic compounds and pharmaceutically acceptable salts thereof. The compounds inhibit IRAK4 and FLT-3 kinases.

Devices and methods for reducing or limiting bleeding in an animal by stimulating the spleen with focused ultrasound (FUS). The devices and methods can be used to treat blood disorders such as hemophilia, or to reduce bleeding during surgery or due to trauma. The methods can be administered to a patient non-invasively by applying ultrasound energy transcutaneously.

The invention belongs to the technical field of biological detection, and particularly relates to an immunodetection reagent for blood virus screening and a preparation method of the immunodetection reagent. The immunodetection reagent comprises the following raw materials in parts by weight: 100 parts of a capture reagent, 300 parts of a sealing agent, 300 parts of a cracking agent, 1 part of an HCV recombinant antigen, 1 part of an anti-HCVcAg monoclonal antibody, 0.2-0.6 part of hydroxymethylcoumarin, 10 parts of BSA, 2-6 parts of glutaric anhydride, 4-8 parts of TEOS and 100 parts of a PBS buffer solution. According to the present invention, the silica microsphere with the HCV recombinant antigen and the anti-HCVcAg monoclonal antibody coupled on the surface and the hydroxymethylcoumarin signal molecule loaded inside is constructed, and the HCV antigen and the HCV antibody in the serum are specifically recognized so as to achieve the efficient diagnosis and detection of the HCV infection in the whole cycle;

Provided herein are antibodies, compositions, and methods of use thereof. The disclosed antibodies bind to von Willebrand factor in blood plasma of a subject. Such antibodies are useful for methods of treatment, such methods of treating one or more blood disorders characterized by excessive bleeding. Also provided herein are methods of treating blood disorders by administering a combination of an anti-VWF antibody and von Willebrand Factor.

1. The name of this design product: Embedded medical air sterilizer. 2. Application of the product with this design: For use in indoor air disinfection in medical and health institutions such as operating rooms, delivery rooms, hematology wards, burn wards, protective isolation wards, intensive care units, and in public places such as schools, offices, and shopping malls. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

The invention relates to the technical field of medical image processing, in particular to a blood disease classification-oriented bone marrow cell multi-scale identification method, which comprises the following steps of: constructing and training a bone marrow cell identification model, and inputting an image to be identified into the trained bone marrow cell identification model to obtain an identification result; the bone marrow cell recognition model comprises a hierarchical feature extraction module, a feature enhancement module, a class center learning framework module and a multi-layer perceptron; compared with an existing model, the classification number and accuracy of cell classification are improved, preliminary diagnosis of hematologic tumor diseases can be achieved in an auxiliary mode, and the examination time is shortened.

The present disclosure provides improved compositions and methods for detecting, diagnosing, prognosing, monitoring, and treating hematological disorders including multiple myeloma in a subject. In particular, the disclosure provides methods for detecting IL4I1 in subjects to reliably diagnose, predict survival, or monitor multiple myeloma in the subject and methods for inhibiting IL4I1 to treat multiple myeloma in the subject.

The present invention relates to a controlled-release pharmaceutical composition comprising at least a controlled-release pharmaceutical dosage form containing EPAG, the controlled-release pharmaceutical composition being suitable for local injection into an affected area. The present invention also relates to a controlled-release pharmaceutical composition in powder form for preparing the pharmaceutical composition suitable for local injection, and a kit for preparing the pharmaceutical composition comprising an aqueous injection vehicle and a controlled-release dosage form or a mixture of controlled and immediate-release dosage forms containing EPAG, the pharmaceutical composition optionally including an excipient. The composition is useful for local injection in patients to improve stem cell homing and / or treat non-malignant hematological disorders, malignant hematological diseases, primary immunodeficiencies, autoimmune diseases, inborn errors of metabolism, and / or degenerative diseases / injuries.

This application relates to the field of medical technology, providing an automated control method and system for hematological medical devices. The method includes: acquiring operating status information of a fluid infusion device; determining whether there is an infusion abnormality in the target fluid within the infusion line based on the operating status information of the fluid infusion device; when an infusion abnormality exists in the target fluid within the infusion line, acquiring acoustic information generated by the target fluid flowing in the infusion line; determining the viscosity coefficient of the target fluid based on the acoustic information; acquiring the actual pumping efficiency of the fluid infusion device; and determining an infusion control strategy for the fluid infusion device based on the actual pumping efficiency and the viscosity coefficient of the target fluid. This solution can improve the accuracy of medical device control.

KLRB1-binding agents (particularly anti-KLRB1 antibodies and antigen-binding portions thereof) and compositions thereof, and therapeutic methods using such agents, for example, to deplete or inhibit cells or activate cells (particularly Th17, Th17.1, ex-Th17, Tc17, MAIT, iNKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo) for the treatment of autoimmune diseases, allergic diseases, transplant rejection, malignant hematological diseases, and cancer.

Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.

The present invention relates to compounds and compositions for the treatment of hematological diseases. The present invention provides methods of treating hematological disorders, such as acute myeloid leukemia, using substituted heterocyclic compounds and pharmaceutically acceptable salts thereof. The compounds inhibit IRAK4 and FLT-3 kinases.

Relates to the field of biological medicine, in particular to a specific recognition MASP3 antibody and application thereof, and the antibody has high human MASP3 affinity and alternative pathway inhibitory activity. The invention further relates to a multispecific antibody which specifically binds to MASP3 and MASP2, and a pharmaceutical composition comprising the antibody which specifically binds to MASP3 and the antibody which specifically binds to MASP2 and / or the multispecific antibody, the antibody or the composition is used for preparing a medicament for treating autoimmune diseases, transplantation-related diseases, inflammatory diseases, hematological diseases, coagulation diseases, angiogenesis-dependent diseases and / or virus infectious diseases.

The application provides a gene set and kit for evaluating the curative effect after allogeneic hematopoietic stem cell transplantation of hematopathy, and belongs to the field of gene detection. The application develops a new post-transplantation curative effect evaluation panel detection design method. The panel comprises: 1. single nucleotide polymorphism (SNP) sites characteristic of individual genetic characteristics, which can be used for graft implantation evaluation; 2. high-frequency mutation sites of blood tumor hotspot genes, which can be used for MRD detection and disease state evaluation; and 3. HLA gene characteristic SNP sites on the short arm of human chromosome 6, which can be used for HLA gene typing, combined with the state of graft implantation, to analyze the occurrence of HLA-loss. The technical scheme of the application can solve the above-mentioned multiple contents of post-transplantation curative effect evaluation at one time, is more accurate and sensitive than the previous detection method, and can greatly reduce the detection cost and shorten the clinical report time.